Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia

Conclusion: From the perspective of the analysis, the addition of dapagliflozin to standard treatment is a cost-effective option in patients with heart failure with reduced ejection fraction in Colombia.PMID:34702123 | DOI:10.1080/14737167.2022.1997595

Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 27, 2021 Category: Health Management Authors: Yaneth Gil-Rojas Pieralessandro Lasalvia Ángel García Source Type: research